

Herantis Pharma R&D Investor Day Highlights

Herantis Pharma Plc, Company release, 8 June 2021 at 11:00 EEST

“We are delighted to host this R&D Day event, and very much look forward to providing an update on the new Herantis as a pure play CNS company and our programs fully focused on disease modifying therapeutics to address the unmet need in Parkinson’s Disease and other neurological illnesses”, commented Dr. Craig Cook, CEO of Herantis. “We are at a key juncture for the company, with solid fundamentals, fascinating science, exciting and meaningful data as we enter the next chapter for the company and our xCDNF and CDNF assets. We are very grateful to the patients, investigators and other medical professionals involved who have helped us get to this point.”

Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases will today (13:00 CEST) host an R&D Investor Day virtually. Herantis’ business executives and scientific leadership will share progress in advancing its R&D pipeline, and external experts will provide the latest perspectives on Parkinson’s disease and its treatment. The full program and the link to the event are available here: <https://herantis.com/press-releases/herantis-pharma-hosts-virtual-rd-investor-day-on-june-8-2021/>

The R&D Investor Day presentations will cover:

- The important milestone and data achieved with the recently announced selection of xCDNF candidate to be taken forward into further development
- Novel evidence of biological and biomarker impact in humans from the CDNF Phase 1 clinical study
- The unmet medical need for the treatment of Parkinson’s disease (PD) and the patient’s perspective

Dr. Craig Cook, CEO of Herantis, will provide a company overview and discuss the company’s transition to be a CNS focused company and the potential that has unlocked. He will also touch on the company’s xCDNF compound selection and provide the emerging picture for CDNF.

Prof. Bastiaan R. Bloem, Radboudumc Center of Expertise for Parkinson & Movement Disorders, will take an engaging and detailed look into Parkinson’s disease, the global perspective of the disease approaching pandemic proportions, and what can be done. In his presentation, he will cover the current global situation, the vast unmet medical need for PD, and the emerging potential of novel approaches.

Dr. Henri Huttunen, CSO of Herantis, will cover the successfully completed engineering and selection of xCDNF candidate HER-096 that will be taken forward into further development. Dr. Huttunen will explain the benefits of HER-096 and provide a compelling data overview regarding its **mechanism of action, high neuroprotective potency, its ability to convincingly**

cross the blood-brain-barrier, and how it can be vital for the life-long maintenance of neuronal function.

Dr. Magnus Sjögren, CMO of Herantis, will discuss the strong merits of CDFN as an emerging biological. Dr. Sjögren will focus on the **compelling biomarker signature of CDFN that strongly supports its ability to restore proteostasis, impact the markers of disease, and correlations with motor and imaging improvements in patients.** He will cover, in detail, CDFN's first-in-human Phase I clinical trial, demonstrating that CDFN is **safe and well tolerated**, and the **very promising effects on biology and biomarkers.**

Mr. Russell Patten, Director General of the European Parkinson's Disease Association (EPDA), will touch on the patient's perspective and how it affects everyone differently. He will provide insight into how people with PD engage with research, the barriers that exist, opportunities and areas of interest. Additionally, he will explain how EPDA supports the global Parkinson's community in the search for a cure.

Prof. Håkan Widner from Skåne University Hospital, Sweden, and Herantis CDFN Study investigator, will examine the path forward for PD, from a clinician's point of view. This will cover the pathology of PD and its progression, diagnosis, potential types of treatments and therapeutic targets. He will also discuss data on emerging novel treatments for PD and their respective potential.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson's Disease, Alzheimer's and other diseases. CDFN is a protein that occurs naturally in the body whose normal role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDFN – a biological protein – is Herantis' lead program and a clinical stage asset; and HER-096 – a synthetic peptidomimetic version of CDFN – is Herantis' follow-on program. Both CDFN and HER-096 have, via their multimodal mechanism of action, the potential to improve neuronal survival and function, and to stop the progression of Parkinson's and other neurodegenerative disease and have a significant therapeutic impact on the lives of patients.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit <https://www.herantis.com>

For more information, please visit <https://www.herantis.com>